US Pharma MarketingGSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.
Source: Pharmaceutical Technology